Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Double Lutein Blue is a sterile, non-toxic intraocular staining solution used as a surgical adjunct in vitreoretinal surgery, specifically for the visualization and peeling of the internal limiting membrane (ILM) and epiretinal membrane (ERM). Developed by Alfa Instruments and distributed globally by Bausch + Lomb, the formulation contains 2% soluble lutein, 0.05% Pure Benzyl-Brilliant Blue (PBB), and 0.15% trypan blue. The inclusion of lutein provides a dual benefit: it acts as a natural blue light filter and an antioxidant, protecting the retina from potential iatrogenic damage caused by the high-intensity light of the endoilluminator during surgery. PBB is a high-purity dye with a specific affinity for the ILM, while trypan blue stains the ERM, enabling surgeons to clearly distinguish and safely remove these delicate tissues. The product is CE-marked and intended to improve surgical precision while minimizing retinal toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Double Lutein Blue.